News from ASH 2019

Excerpt

The 61st ASH (American Society of Hematology) annual meeting and exposition was held in Orlando (FL, USA), December 7–10, 2019, with more than 25,000 attendees from more than 115 countries and almost 4900 featured abstracts. The constantly growing information overload at such “mega-meetings” does not always make it easy to keep an overview and separate the wheat from the chaff. I am happy and grateful that specialists with proven preclinical and clinical expertise in their field have agreed to do this job for us. In this issue of MEMO, selected highlights from the ASH meeting 2019 regarding chronic lymphocytic leukemia, aggressive B‑cell lymphomas, multiple myeloma, and chronic myeloid leukemia are summarized by these experts. The latest developments in chimeric antigen receptor (CAR)T-cell therapy, also a main topic at ASH 2019, have been covered in the March issue of this journal [1]. …